initi outperform rate
initi coverag development-stag biotechnolog
compani work neoantigen address non-smal cell lung cancer nsclc
melanoma bladder cancer well solid tumor outperform
rate month target price
neon current one experiment clinic compound
develop two preclin program experiment compound neo-
person neoantigen vaccin design manufactur
includ immunogen antigen select present patient tumor
current evalu combin checkpoint inhibitor phase
estim neon therapeut first product revenu
result total revenu year million potenti grow
billion success current plan indic
estim year-end expens increas
million million sg expens increas million
million oper loss increas loss million loss
dilut ep expect neg potenti turn posit
assum strategi neon fulli develop commerci
compound estim neon need rais approxim
million fund program current estim
launch year
trade rang
neon leader
field neoantigen-target therapi
dedic transform treatment
cancer direct immun
analyst certif import disclosur see disclosur
estim first product revenu
result total revenu year million potenti
grow billion success
estim neon oper loss continu
launch first compound compani turn profit
revenu start meaning off-set loss
dilut ep expect neg turn
posit
estim sell price experiment product
low neon gain fda approv indic
model market penetr rapid
estim would signific upsid estim
compani neon stage develop
preapprov primarili focu potenti futur revenu
valu compani base expect neon
launch first product estim neon total
revenu increas billion howev
case development-stag compani estim
carri degre risk
acknowledg possibl signific downsid
estim due inher risk drug develop
worst case neon stock could littl valu
appli biotech group averag price-to-sal ratio risk discount revenu million billion
discount arriv valu billion discount invest return six half year arriv valu
million per share
biggest risk product candid possibl gain fda approv therefor becom commerci product
gain fda approv risk includ manufactur secur favor price third parti reimburs
patient drug cost patient behavior physician adopt product maintain patent protect structur chang
tabl content
financi summari
summari potenti near-term
anticip data releas regulatori
initi coverag development-stag biotechnolog
compani work neoantigen address non-smal cell lung cancer nsclc
melanoma bladder cancer well solid tumor outperform rate
month target price anticip neon commerci
development-stag drug nsclc melanoma bladder cancer
compani neon stage develop pre-approv primarili focu
potenti futur revenu valu compani base expect neon
launch first product next seven year estim neon total revenu
increas billion howev case development-stag
compani estim carri degre risk
accord proprietari databas averag forward price-to-sal
biotechnolog sector discount estim revenu billion
risk failur invest return arriv target price
howev acknowledg possibl signific downsid estim due
inher risk drug develop worst case neon stock
could littl valu
valuat methodolog compani depend development-stag
product meaning percentag estim futur earn base appli
industri price-to-earnings multipl price-to-earnings growth rate ratio price-to-sal multipl
estim futur earn revenu discount valu base
estim risk failur use biotechnolog group multipl deriv averag
multipl compani profit sever year exhibit defin
biotechnolog industri equal weight stock biotechnolog compani
posit earn
exhibit price-to-earn price-to-earnings price-to-earnings growth price-to-sal ratio calcul
base price group last day month consensu earn per share
estim forward year sourc data use calcul
databas compil maintain oppenheim co use estim factset price
quot servic
typic appli averag multipl futur estim revenu earn
determin discount rate base compani stage develop use risk
failur base phase develop publish tuft center studi
drug develop base data failur rate potenti drug phase
develop approxim progress phase ii develop
failur rate approxim progress phase develop
failur rate approxim actual file approv
food drug administr failur rate
pipelin one experiment clinic therapi two pre-
clinic candid first anticip commerci impact
result product sale would account neon revenu
phase clinic trial calcul combin weight averag risk
discount neon potenti revenu
summari appli biotech group averag price-to-sal ratio
risk discount revenu million billion discount arriv
valu billion discount invest return six half year
arriv valu million per share
neon leader neoantigen field cancer immunotherapi
focus key scientif capabl includ mass spectrometri bioinformat cell
biolog peptid chemistri person manufactur immun monitor key
scientif capabl support multipl clinic strategi target neoantigen deliv
potent attack tumor aim creat deepen anti-tumor immun
respons broaden rang cancer treatabl via immuno-oncolog
approach headquart cambridg massachusett
privat compani launch neon develop therapi target neo-antigen
abnorm protein produc cancer cell also develop person cell
therapi leverag strength platform epitop predict immun
monitor neoantigen compani advanc clinic
introduct tumor neoantigen
neon work intersect immunolog cancer biolog develop
person tumor neoantigen-bas vaccin way background genet defect
establish hallmark cancer everi tumor uniqu genom alter
found normal cell alter drive malign varieti
mechan activ oncogen suppress tumor suppressor and/or
manipul gene express tradit target therapi approach cancer
treatment focus drug specif alter driver oncogen
brr-abl block cell growth howev major
mutat cancer consid passeng mutat aris due genom
instabl affect fit tumor importantli mutat lead
creation new antigen known tumor neoantigen absolut uniqu
tumor cell recogn target immun system
tumor neoantigen highli clinic relev recent clinic data demonstr
tumor neoantigen burden often correspond clinic benefit checkpoint therapi
therefor tumor neoantigen load may import biomark respons
immunotherapi neon gritston other develop tool predict
neoantigen directli tumor sequenc data creat tumor neoantigen-
base vaccin elicit favor anti-tumor immun respons
neon tumor neoantigen discoveri deliveri platform involv four major step
outlin
biopsi neon plan obtain patient tumor dna routin biopsi part
standard diagnost workup mani solid tumor
neoantigen predict neon use next-gener sequenc identifi mutat
present tumor normal cell although rel straightforward
identifi tumor-specif mutat predict mutat give rise immunogen
peptid first neoantigen rare current estim approxim
mutat form real neoantigen therefor even highli mutat cancer like
melanoma lung cancerwhich anywher sever hundr
uniqu mutationswould predict less bona fide neoantigen
second current public avail predict algorithm low-predict valu
gener mani fals posit neg improv predict accuraci neon
develop proprietari algorithm known recon base mass
spectrometri sequenc larg peptid librari cell line
packag deliveri neon creat put neoantigen peptid per
patient peptid deliv subcutan inject combin
poly-iclc adjuv stimul immun system
neoantigen attract therapeut target
tumor neoantigen attract therapeut target
specif patient tumor mutat present tumor
normal cell potenti form immunogen antigen exclus
tumor therefor reduc risk therapy-induc autoimmun off-
neoantigen identifi routin tumor biopsi sampl current
neon compani field use tumor biopsi collect genom
dna biopsi alreadi part routin diagnost workup mani solid
tumor procedur would creat addit patient burden addit next-
gener sequenc longer cost-prohibit discuss howev
predict immunogen tumor antigen trivial exercis
straightforward product predict immunogen neoantigen easili
manufactur packag inject patient discuss next section
neon util heterolog prime/boost vaccin strategi drive durabl
potenti combin exist immun oncolog therapi tumor
neoantigen demonstr enhanc anti-tumor cell activ
neoantigen target approach may potenti combin
exist immunotherapi approach bi-specif antibodi bite/dart
car-t cell other
potenti off-the-shelf neoantigen vaccin discuss neoantigen-
base vaccin potenti custom patient howev neon
also develop vaccin tumor neoantigen common across mani
differ tumor would allow off-the-shelf vaccin would requir
custom neon current evalu sever recurr mutat
frequent observ predict give rise tumor-specif
financi summari outlook
estim first product revenu result
total revenu year million potenti grow billion
success current plan indic
estim revenu result expect neon launch first product
estim neon oper loss continu
launch first compound compani turn profit revenu
start meaning off-set loss dilut ep expect neg
turn posit estim neon need rais approxim million
fund program current estim launch neo-pv-
summari potenti near-term product
neon current one experiment clinic compound develop
small cell lung cancer nsclc bladder cancer compound
person neoantigen vaccin design manufactur includ immunogen
antigen select present patient tumor current evalu
combin checkpoint inhibitor phase ib clinic trial
estim could sale model
launch second-lin melanoma nsclc bladder cancer
detail expect drug section report appendix
current estim could result product sale
compani websit sec file
person neoantigen vaccin custom-design manufactur base
uniqu mutat fingerprint individu patient technolog
develop base work neon founder dana-farb cancer institut
broad institut mit harvard result clinic result publish journal
natur result demonstr abil person neoantigen vaccin
gener highli specif immun respons six patient stage iii/iv melanoma
treat adjuv set six patient disease-fre median month
initi vaccin current evalu on-going phase ib
clinic studi combin checkpoint inhibitor metastat melanoma non-smal
cell lung cancer bladder cancer detail inform appendix
person neoantigen cell therapi consist multipl cell popul
gener target individu patient uniqu set neoantigen initi
clinic develop solid tumor neon expect file clinic
trial applic cta europ first half evalu
clinic trialsproduct indicationpartner/licensediscoverylead nivolumabmetastat melanoma non-smal cell lung cancer bladder pembrolizumab chemometastat non-smal cell lung cancer antagonist hematolog tumorsselect neoantigen share antigen targetspre-clin ntgn outperform
neon first product candid neon select approach
vaccin target preval mutat er breast cancer current
preclin develop ind file expect first half neon plan
examin potenti across diseas stage combin hormon
chemotherapi target therapi neon expect complet valid sever
addit share neoantigen target
anticip data releas fda file
base neon current pipelin new entiti summar expect
data news releas exhibit
exhibit expect data news releas base compani inform
calcul base studi enrol rate compani websit press releas
base neon current pipelin new entiti summar expect
regulatori file exhibit
exhibit expect regulatori file base compani inform
calcul base studi enrol rate compani file websit press releas
present
product candidateindicationstudyexpect time nsclc bladder cancerphas ib data ib data candidateindicationstudyfilingexpect time phase ib tumorsphas undisclos phase neon
manag board
continu next page
name salari bonusopt award stock award exercis option share own experi summary/ career highlightshugh odowd chief execut chief execut offic hugh odowd join compani bring year expertis pharmaceut leadership move import oncolog therapi clinic develop commerci hugh join novarti oncolog spent year varieti leadership role includ chief commerci offic head global strategi novarti oncolog role respons global commerci oncolog portfolio includ global brand leadership health econom price earli phase commerci develop strateg capabl busi develop licens global sale excel hugh began career pharmaceut glaxo sale move novarti follow career increas level respons sale market took lead role commerci gleevec assum country- region-level commerci leadership role overse entireti novarti oncolog commerci strategi sinc hugh countri presid gener manag novarti unit kingdom ireland hugh hold ba loyola univers chicago kellstadt graduat school busi depaul univers chicago richard gaynor presid research gaynor join recent hold posit senior vice presid global product develop medic affair sinc lilli oncolog total dr gaynor spent year relat senior role lilli oncolog led preclin earli clinic research direct biomark research group serv key compani portfolio review committe dr gaynor began career academia spend nine year faculti ucla school medicin follow year faculti ut southwestern medic school includ time serv chief hematology-oncolog director simmon cancer center dr gaynor move began industri career overse oncolog drug discoveri earli clinic develop dr gaynor chair lilli oncolog research develop committe help overse varieti collabor includ bristol-my squibb merck astrazeneca ge author nearli public particip numer board committe includ sever stand cancer scientif advisori committe md anderson moon shot advisori board damon runyon cancer research foundat acceler cancer cure dr gaynor hold md univers texa southwestern medic school follow resid intern medicin complet fellowship train hematology-oncolog ucla school medicin robert ang chief busi ang chief busi offic respons span fundrais partner intellectu properti public relat prior neon robert serv senior vice presid busi develop bavarian nordic intern biotechnolog compani develop manufactur novel cancer immunotherapi vaccin infecti diseas role robert primarili respons conduct transact bavarian nordic bristol-my squibb prostvac phase immuno-oncolog asset landmark deal march prior join bavarian nordic robert serv head busi develop execut licens transact terumo corpor also serv vice presid medic affair respons medic inform includ call center standard respons product dossier medic scienc liaison group public grant phase clinic studi pharmacoeconom manag team fte prior cadenc robert work frazier healthcar ventur lead healthcar ventur capit firm frazier led two invest round alongsid invest pharmaceut biotechnolog includ inclin medicin compani collegium spun precis dermatolog prior found venture-fund early-stag pharmaceut compani serv chief oper offic primarili respons regulatori intellectu properti matter robert also experi manag consult boston consult group gener surgic resid train robert hold md univers western australia honor columbia busi school yasir al-wakeel ch chief al-wakeel bm ch join first full-tim chief offic recent yasir serv chief offic head corpor develop spearhead strateg sale inivyd gener version doxil ipsen sa billion yasir previous serv variou capac credit suiss invest bank firm serv recent director healthcar invest bank focus biotechnolog prior role equiti research analyst cover biotechnolog specialti pharmaceut sector join credit suiss practic physician hold clinic academ medic post yasir hold bm ch doctor medicin oxford univers theolog cambridg univers comment neon manag extens deep biopharmaceut experi ntgn outperform
continu next page
board directorsagedirector salaryopt award stock award exercisbl option share own affiliation/ highlightscari pfeffer md chairman third ventur partner cari pfeffer chairman board director join third ventur incept year busi develop transact experi along broad array biotech product develop experi cari lead third partner develop effort includ build maintain strong relationship work larg biotech pharmaceut compani play instrument role number innov allianc collabor compani build effort across third portfolio includ industry-lead global strateg collabor agio celgen field cancer metabol nurix celgen field ubiquitin ligas cari support advis busi develop effort across third portfolio also assum activ leadership role portfolio compani function chief execut offic chief busi offic first month launch cari interim chief busi offic interim ceo current serv board member ablexi edim join third cari found pfeffer group boutiqu consult firm provid busi develop strategi advisori servic complet multipl transact lead biotechnolog life scienc compani prior cari spent decad biogen held varieti senior execut level us global manag role focus busi market develop product develop commerci oper earlier career cari spent sever year corpor financ health invest bank group lehman brother cari earn md univers pennsylvania wharton school univers pennsylvania hold ba biochemistri columbia univers robert kamen phd entrepreneur-in-resid third kamen sinc bob kamen serv entrepreneur-in-resid third ventur bob focus format develop biolog compani develop life-chang therapi patient bob bring year leadership experi pharmaceut biotechnolog industri prior third bob serv presid abbott bioresearch center oversaw discoveri product humira first fulli human antibodi product achiev market approv world top sell pharmaceut also member abbott pharmaceut execut manag committe bob presid basf bioresearch corpor year acquir retir abbott chairman co-found bioasset develop corp biotherapeut compani focus spinal diseas acquir cephalon earlier career led discoveri pioneer biotech compani genet institut inc current serv director harbour antibodi bv lycera corp opson advis biopharmaceut compani bob hold biophys amherst colleg ph biochemistri molecular biolog harvard univers academ scientif career work dna tumor virus imperi cancer research laboratori london eric lander phd found director broad lander one drive forc behind today revolut genom current serv found director broad institut eric also professor biolog massachusett institut technolog professor system biolog harvard medic school innov genom technolog key leader human genom project today eric use knowledg human genom tackl fundament issu medicin find caus versu symptom diseas also success entrepreneur found scientif advisor millennium pharmaceut infin pharmaceut eric hold ph mathemat oxford rhode scholar join whitehead institut found whitehead institute/massachusett institut technolog center genom research taught manageri econom faculti harvard busi school odowd chief execut chief execut offic hugh odowd join compani bring year expertis pharmaceut leadership move import oncolog therapi clinic develop commerci hugh join novarti oncolog spent year varieti leadership role includ chief commerci offic head global strategi novarti oncolog role respons global commerci oncolog portfolio includ global brand leadership health econom price earli phase commerci develop strateg capabl busi develop licens global sale excel hugh began career pharmaceut glaxo sale move novarti follow career increas level respons sale market took lead role commerci gleevec assum country- region-level commerci leadership role overse entireti novarti oncolog commerci strategi sinc hugh countri presid gener manag novarti unit kingdom ireland hugh hold loyola univers chicago kellstadt graduat school busi depaul univers chicago
neon sec file compani websit
stephen sherwin md clinic professor medicin univers california san sherwin current divid time advisori work life scienc industri patient care teach specialti medic oncolog clinic professor medicin univers california san francisco volunt attend physician hematology-oncolog zuckerberg san francisco gener hospit advisori work dr sherwin serv director ventur partner third ventur also member scientif steer committe parker institut cancer immunotherapi previous dr sherwin chairman chief execut offic cell genesi cancer immunotherapi compani compani merger also co-found chairman abgenix antibodi compani acquir co-found chairman ceregen gene therapi compani acquir sangamo bioscienc dr sherwin held variou posit clinic research genentech recent vice presid prior staff nation cancer institut addit dr sherwin previous serv board director biotechnolog industri organ chairman member presid council advisor scienc technolog pcast work group drug develop dr sherwin hold ba biolog yale univers md harvard medic school board-certifi intern medicin medic oncolog fellow american colleg physician meryl zausner serv member neon board director sinc decemb ms zausner work novarti inc novarti corpor variou leadership posit retir end june ms zausner serv certifi execut coach senior execut novarti ms zausner chief administr offic novarti inc member execut committe global financ leadership ms zausner chief offic execut vice presid novarti corpor unit state ms zausner member board director multipl myeloma research foundat chair audit committe member board director deirdr hous advocaci center children victim abus neglect ms zausner receiv bs econom account univers albani new york board director believ ms zausner qualifi serv board director given vast experi pharmaceut industri experi chief financi offic life scienc industri robert tepper md partner third tepper co-found third ventur distinguish scientist year experi build oper lead organ biotech industri bob focus format develop scientif strategi third portfolio compani well identifi evalu new invest also assum leadership role number third portfolio compani previous serv interim chief scientif offic bob current serv board member allena prior join third bob presid millennium vital expans drug discoveri compani fulli integr biopharmaceut compani earlier bob co-found cell genesys/abgenix bob hold ab biochemistri princeton univers receiv harvard medic school bob current serv adjunct faculti member harvard medic school massachusett gener hospit advisori board member sever lead health care institut includ partner care center person genet medicin harvard medic school tuft medic school bob board overs tuft univers also serv council nation center advanc translat scienc ncat nation institut nih comment neon board mix impress scientists/physician well repres ventur commun seven director independ ntgn outperform
neon current reliant third-parti contract manufactur
preclin clinic product candid neon consid build
revenu estim revenu launch first
product estim occur base outlook neon could
launch first two potenti drug estim revenu could increas
billion
estim year-end expens increas million
million sg expens increas million million oper
loss increas loss million loss million
assum neon fulli develop commerci compound without
addit partner strateg investor estim oper loss increas
next five year compound-annual-growth-rate compani turn profit
revenu start meaning off-set loss estim oper incom
million scenario estim sg expens
increas averag per year next five year respect
line industri averag percentag product sale
dilut ep expect neg turn posit
estim oper cash flow neg
neon neg oper cash flow expect off-set financ activ
assum strategi neon fulli develop commerci compound
estim neon need rais approxim million
fund program current estim launch year
estim suffici cash fund develop
program estim neon need approxim million
addit cash
believ success next seven year highli depend
fda approv launch current experiment clinic compound
biggest risk product candid possibl gain fda approv
therefor becom commerci product gain fda approv
risk includ manufactur secur favor price third parti
reimburs patient drug cost patient behavior physician adopt product
maintain patent protect structur chang healthcar market
addit stock somewhat limit float could exacerb stock price volatil
convers estim sell price experiment product low
neon gain fda approv indic model market
penetr rapid estim would signific upsid
follow exhibit provid histor project incom statement exhibit
balanc sheet exhibit cash flow exhibit statement along product detail
experiment therapi exhibit
exhibit incom statement histor estim
neon nasdaq-ntgn oppenheim co incom statement leah rush cann thousand except per share product licens contract good marginnmnmnmnmnmnmnmnmnmnminterest incom incom per per share dilut share share compani data oppenheim co estimatesaddit inform avail upon request neon
exhibit balanc sheet histor estim
neon therapeut nasdaq-ntgn oppenheim co balanc sheet leah rush cann thousand except per share asset restrict short-term restrict cash prepaid expens current long-term stockhold equitycurr liabil account current current long-term equiti prefer common addit paid-in accumul comprehens accumul deficit/retain stockhold liabil compani data oppenheim co estimatesaddit inform avail upon request ntgn outperform
exhibit flow histor estim
nasdaq-ntgn oppenheim co statementleah rush cann thousand except per share flow oper net depreci properti stock-bas amortizatoin premium loss dispos properti chang leas lincent chang fair valu adjust share-bas compens chang fair valu asset liabil current long-term account payabl accru current long term cash provid oper flow invest activ purchas short-term proce sale market purchas properti plant proce properti plant cash provid invest flow financ activ proce issuanc common proce issuanc proce issuanc employe stock proce exercis common stock cash provid financ exhang rate cash cash increas cash cash begin end
exhibit histor estim
neon sale patient populationnon-smal cell lung cancer line cell lung cancer front line line cancer size non-smal cell lung cancer line cell lung cancer front line line cancer penetrationnon-smal cell lung cancer line cell lung cancer front line line cancer treatednon-smal cell lung cancer line cell lung cancer front line line cancer per cours therapi cell lung cancer line cell lung cancer front line line cancer thousand non-smal cell lung cancer line cell lung cancer front line line cancer us sale ex-u sale ww sale compani data oppenheim co estimatesaddit inform avail upon request ntgn outperform
endnot refer exhibit
incid deriv nation cancer institut nci seer incid deriv nation cancer institut nci seer data percentag expect relaps base robert et al nejm incid deriv nation cancer institut nci seer data percentag expect relaps base von der maas et al jco deriv nation cancer institut nci seer per year use checkpoint inhibitor comparitor neon
person neoantigen vaccin design manufactur includ
immunogen antigen select present patient tumor current
evalu combin opdivo nivolumab phase ib clinic trial studi
initi initi clinic result expect may neon
initi anoth phase ib clinic trial evalu combin keytruda
pembrolizumab chemotherapi initi clinic result studi expect
current evalu combin checkpoint inhibitor
treatment melanoma non-smal lung cancer bladder cancer
administ subcutan inject four distinct site
neon on-going phase ib studi administ follow
still experiment therapi therefor establish price
conserv estim potenti price cours therapi
base current price checkpoint inhibitor howev pure
oppenheim co estim neon provid strategi price
neon current evalu two phase studi refer
advanc solid tumor neon plan initi two addit exploratori clinic
trial evalu plan commenc
second half
phase patient melanoma lung bladder cancer
bristol-my squibb sponsor multicent single-arm
phase studi evalu plu adjuv opdivo nivolumab
patient melanoma non-smal cell lung cancer nsclc transit cell carcinoma
bladder achiev complet respons nivolumab
therapi elig patient receiv four inject one vial pool
peptid per inject site adjuv nivolumab mg everi two week
primari endpoint safeti key secondari endpoint includ overal surviv os
progression-fre surviv object respons rate orr immun respons
rate studi design enrol patient initi octob
estim primari complet date decemb anticip data
studi
phase patient lung cancer
neon merck sharp dohm corp sponsor single-arm open-
label phase studi evalu pembrolizumab plu
chemotherapi patient advanc metastat nonsquam non-smal cell lung
cancer nsclc receiv treatment metastat diseas elig patient
receiv pembrolizumab dose mg intraven infus iv plu
chemotherapi carboplatin auc pemetrex everi week
cycl patient receiv adjuv hiltonol poly-iclc
administ subcutan one vial pool peptid per inject site four
distinct site extrem flank continu therapi pembrolizumab
primari endpoint safeti key secondari endpoint includ os orr cbr
durat respons dor rcr initi may estim
primari complet date februari anticip data
base analysi neon patent appendix conclud
patent protect initi expir
base current clinic develop program believ
address market therapi patient melanoma non-smal cell lung
cancer nsclc bladder cancer base data nation cancer institut
nci front-lin second-lin nsclc current affect
patient respect unit state second-lin melanoma affect
patient bladder cancer affect patient exhibit
exhibit histor data data obtain nci seer databas estim preval melanoma
incid preval data nsclc preval melanoma adjust estim yearli incid death
non-smal cell lung cancer type epitheli lung cancer small cell
lung cancer common subtyp nsclc squamou cell carcinoma larg
cell carcinoma adenocarcinoma although nsclc frequent associ
histori cigarett smoke adenocarcinoma may also occur never smoker frontlin
therapi combin target therapi immun therapi surgeri and/or
chemotherapi activ genom alter either gene amplif
gain-of-funct mutat estim occur approxim patient
often mutual exclus known driver mutat treatment
paradigm refer standard data treatment set outlin appendix
bladder cancer divid three type transit cell carcinoma squamou
cell carcinoma adenocarcinoma tumor either papillari tumor
mean wart-lik lesion attach stalk non-papillari tumor non-
papillari tumor much less common invas poorer
prognosi transit cell compris innermost tissu bladder cancer
origin account bladder cancer treatment paradigm
refer standard data treatment set outlin appendix
melanoma malign tumor melanocyt cell make pigment melanin
melanoma develop anywher skin like start trunk
leg stage classif melanoma base follow variabl size
tumor level invas whether tumor spread lymph node
distant site treatment paradigm refer standard data treatment
set outlin appendix
approv estim enter second-lin nsclc melanoma
bladder cancer market market penetr conserv
estim achiev market penetr set penetr
front-lin nsclc exhibit
exhibit penetr rate estim calcul number patient treat given year estim incid
preval opco
sale estim base market penetr estim nsclc
melanoma bladder cancer set averag price per cours therapi
per month base current price checkpoint inhibitor
estim world-wide sale increas billion howev
pure oppenheim co estim neon provid strategi
exhibit estim world-wide sale grow billion
treatednon-smal cell lung cancer line cell lung cancer front line line cancer per cours therapi cell lung cancer line cell lung cancer front line line cancer thousand non-smal cell lung cancer line cell lung cancer front line line cancer us sale ex-u sale ww sale compani data oppenheim co estimatesaddit inform avail upon request ntgn outperform
methodolog collect patent inform
identifi patent drug clinic trial approv
fda yet neon sec file search identifi assigne drug key
term drug name indic search uspto websit identifi
neon patent narrow patent claim patent
identifi relat patent could identifi determin expir patent
protect origin patent relat drug identifi twenti year
file origin patent patent protect expir
individu compani patent identifi narrow indic
conclud key patent protect expir
identifi patent licens dana-farb cancer institut found
uspto exhibit
exhibit patent data uspto
patent date filedd present invent relat immunotherapeut peptid use immunotherapi particular immunotherapi cancer specif invent provid method identifi tumor specif neoantigen alon combin tumor-associ peptid serv activ pharmaceut ingredi vaccin composit stimul anti-tumor respons uspto ntgn outperform
current standard nsclc melanoma bladder cancer
cancer begin lung divid two major type nonsmal cell lung
cancer small cell lung cancer depend cell look microscop
type lung cancer grow spread differ way treat differ
report focus sole nonsmal cell lung cancer accord american
cancer societi incid nonsmal cell lung cancer nsclc unit state
lung cancer rare detect earli stage diseas prognosi
detect later stage diseas extrem poor annual death rate
unit state nsclc
five type nonsmal cell lung cancer cancer cell type grow
spread differ way type nonsmal cell lung cancer name kind
cell found cancer cell look view microscop
squamou cell carcinoma cancer begin squamou cell thin flat
cell look like fish scale also call epidermoid carcinoma
adenocarcinoma cancer begin cell glandular secretori properti
larg cell carcinoma cancer cell larg look abnorm
view microscop
adenosquam carcinoma cancer begin cell look flatten view
microscop cell also glandular secretori properti
undifferenti carcinoma consist cancer cell look like normal cell
accord nci nonsmal cell lung cancer stage accord three variabl
size locat primari tumor metastasi lymph node metastasi
organ tissu
occult hidden stage occult stage cancer cell found sputum mucu
cough lung tumor found lung imag
bronchoscopi primari tumor small assess
stage carcinoma situ cancer limit lung found layer
cell grown top line lung
stage cancer lung normal tissu around tumor
stage ii cancer spread nearbi lymph node chest wall rib
muscl make area bodi neck abdomen
diaphragm thin muscl lung heart separ chest
abdomen mediastin pleura thin membran cover outsid lung
area near heart pariet pericardium outer layer tissu
surround heart
stage cancer either spread lymph node mediastinum middl
area lung contain heart major blood vessel
structur spread lymph node opposit side chest lower
neck stage divid stage sometim treat surgeri
stage iiib rare treat surgeri
stage iv cancer spread part bodi anoth lobe lung
almost patient stage iv nsclc incur standard therapi major
nsclc patient radiat three-drug combin therapi platinum-bas
chemotherapi avastin bevacizumab exhibit small subset patient
egfr- alk-mut posit tumor frontlin therapi radiat target
patient whose tumor lack mutat egfr standard frontlin therapi
platinum-bas chemotherapi commonli cisplatin/gemcitabin
paclitaxel/carboplatin potenti combin avastin bevacizumab base
research publish studi two regimen compar orr rate
howev avastin caus seriou advers event may appropri
patient diseas histolog patient respond frontlin therapi may benefit
mainten therapi howev research support use mainten therapi
mix current standard
patient egfr- alk- mutant posit nsclc treat radiat
target therapi mutat egfr oncogen present approxim
nsclc current three approv frontlin anti-egfr-therapi tarceva
erlotinib iressa gefitinib gilotriff afatinib sever control trial studi
use inhibitor rel standard chemotherapi patient previous
untreat egfr-mut posit nsclc base review literatur three
target therapi demonstr significantli improv rel
chemotherapi effect os mix addit respons
therapi appear highli depend specif egfr-activ mutat
present mutat oncogen less common occur nsclc
patient xalkor crizotinib approv frontlin inhibitor test
standard chemotherapi patient previous untreat alk-mut posit nsclc
studi demonstr treatment xalkor significantli improv orr
rel standard chemotherapi
refractori relaps therapi
patient relaps respond front-lin regimen retreat
platinum-bas chemotherapi becom platinum-resist patient
platinum-resist diseas sever treatment option exhibit immunotherapi
base induc patient immun system attack tumorha
promis two approv immunotherapi set opdivo nivolumab
keytruda pembrolizumab monoclon antibodi therapi
demonstr superior orr data rel docetaxel-bas chemotherapi
although therapi highli similar dose schedul efficaci keytruda
requir companion diagnost test indic patient whose tumor
express high level opdivo express restrict thu
avail larger patient popul anoth option platinum-resist patient
regardless egfr-mut statu egfr-target therapi base review
publish clinic trial effect anti-egfr therapi gilotriff afatinib
patient alk-mut posit tumor fail frontlin xalkor crizotinib
treat zykadia certinib alecensa alectinib howev agent
studi small non-random single-ag studi test
trial design patient selectiontherapyyear result publishedphaseindicationrandomizedcontrolledmulticent median rang st diseasedos regimenfront-linebevacizumab paclitaxel carboplatin bevacizumab day paclitaxel day carboplatin day repeat everi day cycl placebo paclitaxel carboplatin placebo day paclitaxel day carboplatin day repeat everi day cycl cisplatin gemcitabin bevacizumab day cisplatin day gemcitabin day drug repeat everi week cisplatin gemcitabin placebo day cisplatin day gemcitabin day repeat everi week per carboplatin paclitaxel carboplatin auc first day everi week per carboplatin paclitaxel carboplatin auc first day everi week carboplatin gemcitabin day carboplatin auc day repeat everi week twice choic chemotherapi pemetrex cisplatin carboplatin auc everi week maximum cisplatin pemetrex everi day cisplatin everi day previous untreat advanc adenocarcinoma nsclcyyyiiigefitinib vs carboplatin untreat egfr mutant advanc nsclcafatinib vs pemetrex vs paclitaxel vs investig choic untreat recurr advanc nsclcbevacizumab cisplatin gemcitabin vs cisplatin untreat advanc nonsquam nsclcyprevi untreat posit advanc nonsquam nsclcerlotinib vs gemcitabin untreat nsclc egfr mutationsyyyyyybevacizumab paclitaxel carboplatin vs paclitaxel untreat egfr mutant advanc adenocarcinoma nsclci ntgn outperform
efficaci dataefficaci dataefficaci dataevalu patient survivalmdrttporr crpr common toxic patient w/ specif grade toxicitiestri sponsor respons criteria os monthsmedian rate hypertens proteinuria bleed neutropenia febril neutropenia thrombocytopenia hyponatremia rash headacheneutropenia os monthsmedian thrombocytopenia anemia asthenia vomit hypertens venou thromboembol event thrombocytopenia anemia ischem event venou thromboembol event month elev aminotransferas levelsappetit loss rash aminotransferas elev month anemia appetit loss sensori neutropathyappetit loss neuropathi arthralgia neutropenia anemia os monthsmedian elev aminotransferas levelsappetit loss rash aminotransferas elev os monthsmedian anemia sensori neuropathyappetit loss neuropathi arthralgia neutropenia anemia monthsincreas alanin aminotransferas alt skin rashincreas alt monthshigh incid neutropenia thrombocytopenianeutropenia thrombocytopenia anemia disord diarrhea nausea edemaneutropenia elev aminotransferas fatigu vomit decreas appetiteneutropenia anemia leukopenia thrombocytopenia os monthsmedian monthsrash/acn diarrhea paronychia os monthsmedian monthsneutropenia fatigu leucopenia secondari os orrastrazenicaecogf hoffman-la rochef hoffman-la rocheprimari secondari orrboehring ingelheimpfizersafeti dataprimari secondari osjapan societi promot scienceprimari secondari os orrprimari os secondari orrprimari primari neon
trial design patient selectiontherapyyear result publishedphaseindicationrandomizedcontrolledmulticent median rang st diseasedos regimenfront-lin everi week choic carboplatin pemetrex pembrolizumab everi week carboplatin pemetrex everi pemetrex carboplatin pemetrex everi week pembrolizumab carboplatin pemetrex vs carboplatin previous untreat advanc nsclc untreat advanc nsclc vs twice per day trametinib per day dabrafenib untreat nsclc mutationnni ntgn outperform
efficaci dataefficaci dataefficaci dataevalu patient survivalmdrttporr crpr common toxic patient w/ specif grade toxicitiestri sponsor respons criteria os month dor reachedmedian anemia pneumon os month dor monthsmedian neutropenia thrombocytopenia decreas neutrophil count decreas neutrophil count pancytopenia thrombocytopenia secondari secondari ospyrexia alanin aminotransferas increas hypertens vomit pyrexia alanin aminotransferas increas hypertens vomit eject fraction decreasesafeti datanovartisprimari orrmedian
trial design patient selectiontherapyyear result publishedphaseindicationrandomizedcontrolledmulticent median rang st diseasedos everi everi choic chemotherapi vinorelbin day week cycl ifosfamid day week day day day day ramucirumab docetaxel day day cycl ramucirumab day day placebo docetaxel day day cycl everi everi everi everi week afatinib everi week everi week afatinib vs ramucirumab vs docetaxel advanc squamou nonsquam nsclcyyyiiiplatinum-resist advanc squamou cell nsclc yyynivolumab vs vs advanc nsclci everi week vs advanc nonsquam advanc squamou cell nsclc yplatinum-resistnat posit advanc docetaxel vs investig choic advanc nsclcatezolizumab vs advanc nonsquam nsclcyyypemetrex vs advanc nsclcyyyyi ntgn outperform
efficaci dataefficaci dataefficaci dataevalu patient survivalmdrttporr crpr common toxic patient w/ specif grade toxicitiestri sponsor respons criteria os monthsmedian ttp febril neutropenia neurosensori asthenia nausea vomit os monthsmedian tpp febril neutropenia asthenia os monthsmedian tpp asthenia nausea os monthsmedian ttp monthsmedian fatigu os monthsmedian ttp monthsmedian neutropen fever infectionsneutropenia febril neutropenia fatigu os diarrhea anorexia fatiguerash anorexia diarrhea fatigu os fatigu infect os monthsmedian incid neutropenia fatigu febril neutropeniafatigu diarrhea neutropenia leucopenia febril neutropenia os monthsmedian dyspnoea neutropenia leucopenia anemia febril neutropenia year year asthenia year year fatigu alopecia nauseafatigu neutropenia febril neutropenia os monthsmedian decreas appetit os monthsmedian fatigu nausea alopecianeutropenia febril neutropenia leukopenia fatigu os monthsmedian rash/acn os monthsmedian os monthsmedian dor os monthsmedian dor neutropenia febril neutropenia lillyprimari os secondari orrosi pharmaceuticalsprimari os secondari orr durat responseprimari secondari os orrprimari os secondari ttp orrboehring ingelheimbristol-my squibbroche lillyprimari os secondari efficaci accord tumor express levelmedian os ossafeti datamedian os expressionbristol-my squibbmerckfatigu pruritu decreas appetiterhone-poulenc rorerprimari os secondari orrprimari os secondari orr neon
trial design patient selectiontherapyyear result publishedphaseindicationrandomizedcontrolledmulticent median rang st diseasedos regimenrecurr posit first twice choic chemotherapi pemetrex docetaxel everi week recurr posit second line-inhibitor nave-inhibitor intoler posit advanc nsclc twice daili brigitinib per day brigitinib per day ceritinib posit advanc nsclc posit advanc nsclcycrizotinib vs investig choic posit advanc nsclc ntgn outperform
efficaci dataefficaci dataefficaci dataevalu patient survivalmdrttporr crpr common toxic patient w/ specif grade toxicitiestri sponsor respons criteria disord gastrointestin side effect elev liver aminotransferas levelselev aminotransferas level dyspnea alopecia dyspneafatigu month monthsmedian month monthsmedian fatigu peripher edeman/af hoffmann-la rocheprimari nausea vomit fatigu anemia pneumonia aspart aminotransferas increas alanin aminotransferas increas blood alkalin phosphatas increas lipas increas hyperglycemia safeti secondari orr mdr diarrhea nausea vomit fatigu abdomin painpfizersafeti dataprimari secondari orrnausea diarrhea headach cough n/atakedaprimari orr neon
melanoma malign tumor melanocyt cell make pigment melanin
accord american cancer societi incid melanoma unit
state case per year melanoma develop anywher skin
like start trunk leg
stage melanoma
stage classif melanoma base follow variabl size
tumor level invas whether tumor spread lymph node
ulcer spread lymph node organ
stage ia tumor less millimet thick outer layer skin
ulcer spread lymph node organ
stage ib tumor either less thick ulcer thick
ulcer spread lymph node organ
stage iia tumor either thick ulcer thick
thick ulcer spread lymph node organ
stage iib tumor either thick ulcer
stage iic tumor thick ulcer
ulcer spread nearbi lymph node nearbi tissu
stage iiia-c tumor may thick may may
origin site primari tumor
stage iv tumor spread lymph node organ area far
accord nci surgic resect mainstay therapi melanoma
stage i-iii melanoma standard therapi involv excis melanoma potenti
adjuv therapi lymph node manag unresect stage stage iv
melanoma standard approach involv combin intralesion therapi
immunotherapi and/or chemotherapi patient specif oncogen mutat also
treat target therapi exhibit base research publish
studi effect frontlin therapi opdivo nivolumab
monoclon antibodi combin yervoy ipilimumab monoclon
antibodi keytruda pembrolizumab base result studi orr
regimen patient achiev cr approxim
melanoma tumor harbor activ mutat braf gene specif braf
mutat sever approv therapi tafinlar dabrafenib
mekinist trametinib zelboraf vemurafenib cotel cobimetinib base
review literatur agent effect use combin
tafinlar mekinist zelboraf cotel anoth option melanoma patient
intralesion therapi set approv intralesion agent imlyg t-
oncolyt herp simplex viru
relaps refractori
patient relaps standard therapi immunotherapi target therapi base
review literatur effect immunotherapi regimen
inhibitor opdivo nivolumab keytruda pembrolizumab zelboraf also
option patient melanoma nci recommend melanoma
patient enrol clinic trial
efficaci datatherapyyear result publishedphaseindicationrandomizedcontrolledmulticent median rang st diseasedos regimenevalu patient survivalmdrfront-lin stage everi week everi everi week stage /iv dacarbazin ipilimumab dacarbazin given week decarbazin alon everi week week year year dacarbazin placebo given week everi week week year year ipilimumab nivolumab everi week first cycl everi week ipilimumab everi week everi week dose everi week year everi week year everi rate month everi rate month everi week total rate month vs therapi stage resect melanomayyynivolumab vs dacarbazin vs therapi stage resect melanomayyystag /iv previous untreat unresect /iv previous untreat unresect melanomay everi week everi week vs pembrolizumab everi week vs design patient dacarbazin vs placebo dacarbazin ipilimumab vs nivolumab placebo vs ipilimumab placebo untreat unresect metastat /iv previous untreat unresect melanomay ntgn outperform
efficaci datattporr crpr common toxic patient w/ specif grade toxicitiestri sponsor respons criteria median recurrence-fre surviv monthsdiarrhea pruritu rash nausea fatigu headachediarrhea coliti alanin aminotransferas increas aspart aminotransferas increas hypophys recurrence-fre surviv monthsdiarrhea fatigu n/amedian recurrence-fre surviv reachedfatigu diarrhea pruriti rashdiarrhea rash recurrence-fre surviv monthsfatigu diarrhea pruriti rashdiarrhea alanin aminotransferas increas aspart aminotransferas increas rash pruritisincreas alanin aminotransferas increas aspart aminotransferas fatigu pruritusdiarrhea increas alanin aminotransferas increas aspart aminotransferas coliti pruritu nausean/amedian pruritu diarrhea vomitingthrombocytopenia month diarrhea rashn/a month diarrhea rashn/a week diarrhea rash pruritu nausea colitiscol recurrence-fre survivalbristol-my squibbprimari recurrence-fre survivalprimari bristol-my squibbprimari os secondari orr median squibbmerck sharp dohmeprimari ossafeti dataprimari os secondari cr prbristol-my squibb neon
efficaci datatherapyyear result publishedphaseindicationrandomizedcontrolledmulticent median rang st diseasedos regimenevalu patient survivalmdrfront-lin stage iii/iv trametinib dabrafenib twice daili trametinib rate month twice rate month trametinib dabrafenib twice daili trametinib rate twice rate month cobimetinib vemurafenib twice daili cobimetinib day day month placebo vemurafenib twice daili month twice rate month everi rate month twice everi rate month choic chemotherapi dacarbazin everi week paclitaxel everi rate month pfu/ml deliv intralesion follow subsequ dose pfu/ml everi os month mdr deliv subcutan daili day day os monthsmdr design patient selectionyyyybraf previous untreat metastat melanomavemurafenib vs vs previous untreat metastat trametinib vs dabrafenib previous untreat metastat melanomabraf previous untreat unresect metastat melanomadabrafenib trametinib vs vs decarbazin metastat melanoma one previou treatment braf/mek-inhibitor niav iiiyyyvemurafenib cobimetinib vs previous untreat local advanc metastat vs granulocyt macrophag colony-stimul factor iiib/iv unresect melanomay ntgn outperform
efficaci datattporr crpr common toxic patient w/ specif grade toxicitiestri sponsor respons criteria median fatigu nausea headach chill diarhea arthralgia rash hypertensionpyrexia decreas eject fraction fatigu nausea headach chill diarhea arthralgia rash hypertensionhypertens decreas eject cutan squamous-cel carcinoma nausea rash arthralgia diarrhea rash nausea rash alopecia arthralgiarash arthralgia cutan squamous-cel carcinoma keratoacanthoma event arthralgia fatigu photosensit skin reactionsrash cutan squamou cell carcinoma keratoacanthoma alopecia nausea vomit neutropenian/amedian toxic effect fever fatigu arthralgia headachen/amedian vomit neutropenia fatigu asthenianeutropenia thrombocytopenia diarrhea peripher edemarash hypertens nausea constip vomit chill pyrexia nausea influenza-lik nausea influenza-lik illnessn/asafeti dataglaxo smith klineprimari secondari os orrglaxo smith klinehoffmann-la rocheglaxo smith klineprimari secondari os rr durat respons primari secondari os orr durat responseglaxo smith klineprimari os secondari orr durat responseprimari secondari rr respons durat hoffmann-la roche/genentechprimari secondari os orrprimari mdr secondari os orramgen neon
efficaci datatherapyyear result publishedphaseindicationrandomizedcontrolledmulticent median rang st diseasedos regimenevalu patient survivalmdrsecond line everi choic chemotherapi decarbazin everi week carboplatin auc paclitaxel everi week everi month everi month everi month ipilimumab singl dose os os singl dose os monthsvemurafenib braf advanc melanoma follow failur front line twice os monthstrial design patient selectionipilimumab vs ipilimumab vs vs investig choic and/or braf inhibitor-resist advanc melanoma vs melanoma follow failur frontlin therapyy melanoma follow failur frontlin therapyy ntgn outperform
efficaci datattporr crpr common toxic patient w/ specif grade toxicitiestri sponsor respons criteria lipas increas alanin aminotransferas anemia thrombocytopenia anemiaanemia neutropenia immune-rel event gastrointestin fatigu immune-rel event gastrointestin coliti rash photosensit reaction fatigu alopeciaarthralgia rash elev liver enzym cutan squamous-cel carcinoma keratoacanthoma rocheprimari orr secondari ossafeti dataimmunt relat eventsbristol-my squibbbristol-my squibbprimari orr secondari primari osmerck sharp dohmeprimari os neon
locat lower part abdomen bladder store wast collect
kidney pass bodi urethra three type bladder
cancer begin cell line bladder transit cell carcinoma squamou cell
carcinoma adenocarcinoma tumor either papillari tumor mean
wart-lik lesion attach stalk non-papillari tumor non-papillari
tumor much less common invas poorer prognosi
transit cell compris innermost tissu bladder cancer origin
account bladder cancer focu section report
accord american cancer societi incid bladder cancer unit
state
patient prognosi choic treatment bladder cancer determin
stage diseas accord nci bladder cancer stage follow
stage cancer found tissu line insid bladder stage divid
stage stage cancer stage also known papillari carcinoma may
look like tini mushroom grow line bladder cancer stage also
known carcinoma situ look like flat tumor tissu line insid
stage cancer cell spread layer inner line bladder
stage ii cancer cell spread either inner half outer half muscl wall
bladder
stage cancer cell spread bladder fatti layer tissu
surround may spread reproduct organ prostat uteru vagina
stage iv cancer spread bladder wall abdomen pelvi
cancer may spread one lymph node distant part bodi
accord nci small fraction patient stage iv bladder carcinoma
cure main goal therapi patient pain relief front-lin therapi
treatment stage iv bladder cancer includ radic cystectomi remov
bladder alon combin radiat radiat also use stand-
alon front-lin therapi accord nci cisplatin-bas combin chemotherapi
regimen standard care stage iv set exhibit m-vac
regimen contain trexali methotrex velban vinblastin adriamycin
doxorubicin platinol cisplatin therapi shown result
longer surviv random control trial regimen gemzar gemcitabin
platinol cisplatin similar efficaci m-vaccan also use
overal surviv patient develop resist platinum-bas chemotherapi
poor tecentriq atezolizumab monoclon antibodi recent
grant acceler approv set base tumor respons rate durat
respons phase ii studi single-arm studi tecentriq orr
benefit seen patient express greater fact
observ patient cohort low-express
cohort nci recommend enrol clinic trial
therapyyear result publishedphaseindicationrandomizedcontrolledmulticent median rang st diseasedos regimenevalu patient frontlinem-vac methotrex day vinblastin day doxorubicin day cisplatin day repeat everi day cisplatin gemcitabin day cisplatin day urotheli carcinoma elig cisplatin-contain urotheli carcinoma elig cisplatin-contain m-vac regimen methotrex vinblastin doxorubicin cisplatin vs gemcitabin cisplatin metastat transition-cel carcinomaynypembrolizumab ever everi ntgn outperform
therapyyear result publishedphaseindicationrandomizedcontrolledmulticent median rang st diseasedos regimenevalu patient express level express level ever choic urotheli carcinoma elig cisplatin-contain everi urotheli carcinoma failur platinum-bas frontlin therapi everi urotheli carcinoma failur platinum-bas frontlin therapi inelig platinum urotheli carcinoma failur platinum-bas frontlin therapi everi urotheli carcinoma failur platinum-bas frontlin therapi design patient selectionynyatezolizumab everi week ntgn outperform
stock price compani mention report
